Gadoquatrane performs at lower dose than gadobutrol for contrast MRI

Wednesday, November 29 | 3:30 p.m.-3:40 p.m. | W7-SSNR13-4 | Room E353C 

Gadoquatrane lowers the gadolinium dose by 60% compared with current standard of care macrocyclic gadolinium-based contrast agents (GBCAs) for central nervous system (CNS) contrast-enhanced MR imaging, according to this Wednesday afternoon talk.

A team led by presenter Benjamin Pan Liu, MD, of Northwestern Medicine in Chicago, conducted a phase II study that included 50 patients with known or suspected central nervous system lesions. The purpose of the study was to investigate different doses of gadoquatrane in cohorts of 50 evaluable patients per dose level; study participants underwent two contrast-enhanced MRI exams, one with gadobutrol at 0.1 mmol Gd/kg by body weight, and the other with gadoquatrane starting with a dose of 0.04 mmol Gd/kg by body weight.

The primary endpoint of the research was to assess the overall diagnostic preference of three radiologist readers based on blinded exam readings (assessing for signal intensity; contrast-to-noise ratio; and signal-to-noise ratio at 5,10, and 15 minutes post injection). The secondary endpoint was to determine whether gadoquatrane and gadobutrol performed comparably when it came to lesion visualization factors such as contrast enhancement, border delineation, and internal morphology.

The team reported the following:

  • The efficacy of gadoquatrane at a dose of 0.04 mmol Gd/kg bodyweight.
  • Readers' overall diagnostic preference was similar for gadoquatrane and gadobutrol.
  • The sum of lesion visualization parameter scores (scale of 3 to 11) at five minutes post injection was similar for gadoquatrane and gadobutrol (average reader mean score +8.94 and +9 respectively).
  • For all three visualization parameters, the three showed near-zero mean differences between gadoquatrane and gadobutrol, which indicated that there was no performance difference between the agents.
  • Both agents demonstrated comparable signal enhancement parameters at the investigated doses and time points.

"A dose of 0.04 mmol Gd/kg body weight of gadoquatrane has similar efficacy results to 0.1 mmol Gd/kg body weight of gadobutrol and [supports] the further development of gadoquatrane," the group concluded.

Want to know more? Attend this session for further details on the research.

Page 1 of 1